Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 338

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

Open access
Richard, I.H., McDermott, M.P., Kurlan, R., Lyness, J.M., Como, P.G., Pearson, N., Factor, S.A., Juncos, J., Serrano Ramos, C., Brodsky, M., Manning, C., Marsh, L., Shulman, L., Fernandez, H.H., Black, K.J., Panisset, M., Christine, C.W., Jiang, W., Singer, C., Horn, S., Pfeiffer, R., Rottenberg, D., Slevin, J., Elmer, L., Press, D., Hyson, H.C., McDonald, W., Richard, Irene, McDonald, William, McDermott, Michael, Como, Peter G., Kurlan, Roger, Lyness, Jeffrey M., Pearson, Nancy, Sommerfeld, Barbara, Deeley, Cheryl, de la Torre, Tania, Barnard, Michele, Wilson, April, Lincoln, Maryann, Damgaard, Paula, Gerstenhaber, Melissa, Dustin, Kelly, Zappala, Nancy, Swartz, Camille, Creech, Mary, Shipley, Elda, Blankenship, Samantha, Beland, Monica, Roth, Jessie, Burnette, Heather, Foxworth, Tamara, Quesada, Monica, Lloyd, Mary, Pfeiffer, Brenda, Hansen, Joy, Folie, Joy, Wagner, Renee, Spears, Julia, Taylor, Colleen, Brown, Rachel, Iguchi, Lisa, Lim, Chen, LaDonna, Kori, Megens, Julie, Menza, Matthew, Cummings, Jeffrey, Hamer, Robert, Shannon, Kathleen, Odenkirchen, Joanne, Conwit, Robin, Beck, Christopher, LaDonna, Donna, Bausch, Jan, Kim, Scott, Chismar, Ron, Quinn, Sinead, Bean, Steve, Daigneault, Susan, Lindsay, Patricia, Ross, Tori, Kompoliti, Katie·2012·Neurology

Abstract

OBJECTIVE: To evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) and a serotonin and norepinephrine reuptake inhibitor (SNRI) in the treatment of depression in Parkinson disease (PD). METHODS: A total of 115 subjects with PD were enrolled at 20 sites. Subjects were randomized to receive an SSRI (paroxetine; n = 42), an SNRI (venlafaxine extended release [XR]; n = 34), or placebo (n = 39). Subjects met DSM-IV criteria for a depressive disorder, or operationally defined subsyndromal depression, and scored >12 on the first 17 items of the Hamilton Rating Scale for Depression (HAM-D). Subjects were followed for 12 weeks (6-week dosage adjustment, 6-week maintenance). Maximum daily dosages were 40 mg for paroxetine and 225 mg for venlafaxine XR. The primary outcome measure was change in the HAM-D score from baseline to week 12. RESULTS: Treatment effects (relative to placebo), expressed as mean 12-week reductions in HAM-D score, were 6.2 points (97.5% confidence interval [CI] 2.2 to 10.3, p = 0.0007) in the paroxetine group and 4.2 points (97.5% CI 0.1 to 8.4, p = 0.02) in the venlafaxine XR group. No treatment effects were seen on motor function. CONCLUSIONS: Both paroxetine and venlafaxine XR significantly improved depression in subjects with PD. Both medications were generally safe and well tolerated and did not worsen motor function. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that paroxetine and venlafaxine XR are effective in treating depression in patients with PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3182516244

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 338

Metadata

Authors
Richard, I. H., McDermott, M. P., Kurlan, R., Lyness, J. M., Como, P. G., Pearson, N., Factor, S. A., Juncos, J., Serrano Ramos, C., Brodsky, M., Manning, C., Marsh, L., Shulman, L., Fernandez, H. H., Black, K. J., Panisset, M., Christine, C. W., Jiang, W., Singer, C., Horn, S., Pfeiffer, R., Rottenberg, D., Slevin, J., Elmer, L., Press, D., Hyson, H. C., McDonald, W., Richard, I., McDonald, W., McDermott, M., Como, P. G., Kurlan, R., Lyness, J. M., Pearson, N., Sommerfeld, B., Deeley, C., de la Torre, T., Barnard, M., Wilson, A., Lincoln, M., Damgaard, P., Gerstenhaber, M., Dustin, K., Zappala, N., Swartz, C., Creech, M., Shipley, E., Blankenship, S., Beland, M., Roth, J., Burnette, H., Foxworth, T., Quesada, M., Lloyd, M., Pfeiffer, B., Hansen, J., Folie, J., Wagner, R., Spears, J., Taylor, C., Brown, R., Iguchi, L., Lim, C., LaDonna, K., Megens, J., Menza, M., Cummings, J., Hamer, R., Shannon, K., Odenkirchen, J., Conwit, R., Beck, C., LaDonna, D., Bausch, J., Kim, S., Chismar, R., Quinn, S., Bean, S., Daigneault, S., Lindsay, P., Ross, T., & Kompoliti, K.
Venue
Neurology
Published
2012-04-17
Volume
78
Issue
16
Pages
1229-1236
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2074828631
Cited by
338
References
41
FWCI
21.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. https://app.cochat.ai/papers/10.1212/wnl.0b013e3182516244
The paper
Richard, I. H., McDermott, M. P., Kurlan, R., Lyness, J. M., Como, P. G., Pearson, N., Factor, S. A., Juncos, J., Serrano Ramos, C., Brodsky, M., Manning, C., Marsh, L., Shulman, L., Fernandez, H. H., Black, K. J., Panisset, M., Christine, C. W., Jiang, W., Singer, C., . . . Kompoliti, K. (2012). A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. https://doi.org/10.1212/wnl.0b013e3182516244

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.